NO329024B1 - Peptidrensing - Google Patents
Peptidrensing Download PDFInfo
- Publication number
- NO329024B1 NO329024B1 NO20043046A NO20043046A NO329024B1 NO 329024 B1 NO329024 B1 NO 329024B1 NO 20043046 A NO20043046 A NO 20043046A NO 20043046 A NO20043046 A NO 20043046A NO 329024 B1 NO329024 B1 NO 329024B1
- Authority
- NO
- Norway
- Prior art keywords
- solvent mixture
- solvent
- nona
- decapeptide
- sub
- Prior art date
Links
- 239000011877 solvent mixture Substances 0.000 claims abstract description 30
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 26
- IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 claims abstract description 18
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 18
- 238000001556 precipitation Methods 0.000 claims abstract description 15
- 239000002904 solvent Substances 0.000 claims abstract description 14
- 150000001875 compounds Chemical class 0.000 claims abstract description 13
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims abstract description 12
- 238000004090 dissolution Methods 0.000 claims abstract description 10
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims abstract description 9
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 claims abstract description 6
- UAEPNZWRGJTJPN-UHFFFAOYSA-N methylcyclohexane Chemical compound CC1CCCCC1 UAEPNZWRGJTJPN-UHFFFAOYSA-N 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 6
- 239000003960 organic solvent Substances 0.000 claims abstract description 6
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 claims abstract description 4
- 238000005406 washing Methods 0.000 claims abstract description 4
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims abstract description 3
- GYNNXHKOJHMOHS-UHFFFAOYSA-N methyl-cycloheptane Natural products CC1CCCCCC1 GYNNXHKOJHMOHS-UHFFFAOYSA-N 0.000 claims abstract description 3
- TVMXDCGIABBOFY-UHFFFAOYSA-N octane Chemical compound CCCCCCCC TVMXDCGIABBOFY-UHFFFAOYSA-N 0.000 claims abstract description 3
- 235000019260 propionic acid Nutrition 0.000 claims abstract description 3
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 claims abstract description 3
- 238000001035 drying Methods 0.000 claims abstract 2
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 claims description 27
- 238000000034 method Methods 0.000 claims description 22
- 229940124041 Luteinizing hormone releasing hormone (LHRH) antagonist Drugs 0.000 claims description 8
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 6
- 230000001376 precipitating effect Effects 0.000 claims description 6
- 239000002474 gonadorelin antagonist Substances 0.000 claims description 5
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 4
- XBDQKXXYIPTUBI-UHFFFAOYSA-M Propionate Chemical compound CCC([O-])=O XBDQKXXYIPTUBI-UHFFFAOYSA-M 0.000 claims description 4
- FKRCODPIKNYEAC-UHFFFAOYSA-N ethyl propionate Chemical compound CCOC(=O)CC FKRCODPIKNYEAC-UHFFFAOYSA-N 0.000 claims description 4
- DKPFZGUDAPQIHT-UHFFFAOYSA-N Butyl acetate Natural products CCCCOC(C)=O DKPFZGUDAPQIHT-UHFFFAOYSA-N 0.000 claims description 2
- FERIUCNNQQJTOY-UHFFFAOYSA-M Butyrate Chemical compound CCCC([O-])=O FERIUCNNQQJTOY-UHFFFAOYSA-M 0.000 claims description 2
- RMOUBSOVHSONPZ-UHFFFAOYSA-N Isopropyl formate Chemical compound CC(C)OC=O RMOUBSOVHSONPZ-UHFFFAOYSA-N 0.000 claims description 2
- RJUFJBKOKNCXHH-UHFFFAOYSA-N Methyl propionate Chemical compound CCC(=O)OC RJUFJBKOKNCXHH-UHFFFAOYSA-N 0.000 claims description 2
- KXKVLQRXCPHEJC-UHFFFAOYSA-N acetic acid trimethyl ester Natural products COC(C)=O KXKVLQRXCPHEJC-UHFFFAOYSA-N 0.000 claims description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 2
- WBJINCZRORDGAQ-UHFFFAOYSA-N formic acid ethyl ester Natural products CCOC=O WBJINCZRORDGAQ-UHFFFAOYSA-N 0.000 claims description 2
- FUZZWVXGSFPDMH-UHFFFAOYSA-N hexanoic acid Chemical compound CCCCCC(O)=O FUZZWVXGSFPDMH-UHFFFAOYSA-N 0.000 claims description 2
- GJRQTCIYDGXPES-UHFFFAOYSA-N iso-butyl acetate Natural products CC(C)COC(C)=O GJRQTCIYDGXPES-UHFFFAOYSA-N 0.000 claims description 2
- FGKJLKRYENPLQH-UHFFFAOYSA-M isocaproate Chemical compound CC(C)CCC([O-])=O FGKJLKRYENPLQH-UHFFFAOYSA-M 0.000 claims description 2
- OQAGVSWESNCJJT-UHFFFAOYSA-N isovaleric acid methyl ester Natural products COC(=O)CC(C)C OQAGVSWESNCJJT-UHFFFAOYSA-N 0.000 claims description 2
- 229940017219 methyl propionate Drugs 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- WMOVHXAZOJBABW-UHFFFAOYSA-N tert-butyl acetate Chemical compound CC(=O)OC(C)(C)C WMOVHXAZOJBABW-UHFFFAOYSA-N 0.000 claims description 2
- 238000002955 isolation Methods 0.000 claims 1
- 150000002148 esters Chemical class 0.000 abstract 2
- 125000005907 alkyl ester group Chemical group 0.000 abstract 1
- 125000004432 carbon atom Chemical group C* 0.000 abstract 1
- 150000001735 carboxylic acids Chemical class 0.000 abstract 1
- 239000000047 product Substances 0.000 description 17
- 108090000765 processed proteins & peptides Proteins 0.000 description 14
- 108700012941 GNRH1 Proteins 0.000 description 5
- 238000004587 chromatography analysis Methods 0.000 description 5
- 239000000579 Gonadotropin-Releasing Hormone Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 239000005557 antagonist Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 238000004108 freeze drying Methods 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000002953 preparative HPLC Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 108010023617 abarelix Proteins 0.000 description 1
- AIWRTTMUVOZGPW-HSPKUQOVSA-N abarelix Chemical compound C([C@@H](C(=O)N[C@H](CC(N)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCNC(C)C)C(=O)N1[C@@H](CCC1)C(=O)N[C@H](C)C(N)=O)N(C)C(=O)[C@H](CO)NC(=O)[C@@H](CC=1C=NC=CC=1)NC(=O)[C@@H](CC=1C=CC(Cl)=CC=1)NC(=O)[C@@H](CC=1C=C2C=CC=CC2=CC=1)NC(C)=O)C1=CC=C(O)C=C1 AIWRTTMUVOZGPW-HSPKUQOVSA-N 0.000 description 1
- 229960002184 abarelix Drugs 0.000 description 1
- 159000000021 acetate salts Chemical class 0.000 description 1
- RFQIWHDNNZFRBL-UHFFFAOYSA-N acetic acid;ethanol;hydrate Chemical compound O.CCO.CC(O)=O RFQIWHDNNZFRBL-UHFFFAOYSA-N 0.000 description 1
- 239000012736 aqueous medium Substances 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000012043 crude product Substances 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 150000003840 hydrochlorides Chemical class 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000007040 multi-step synthesis reaction Methods 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000003389 potentiating effect Effects 0.000 description 1
- 239000013557 residual solvent Substances 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical class O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
- C07K7/04—Linear peptides containing only normal peptide links
- C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
- C07K1/14—Extraction; Separation; Purification
- C07K1/30—Extraction; Separation; Purification by precipitation
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Analytical Chemistry (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| SE0104462A SE0104462D0 (sv) | 2001-12-29 | 2001-12-29 | Peptide purifcation (Peptidrening) |
| PCT/IB2002/005581 WO2003055900A1 (en) | 2001-12-29 | 2002-12-23 | Peptide purification |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO20043046L NO20043046L (no) | 2004-08-30 |
| NO329024B1 true NO329024B1 (no) | 2010-08-02 |
Family
ID=20286556
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20043046A NO329024B1 (no) | 2001-12-29 | 2004-07-16 | Peptidrensing |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US7057014B2 (enExample) |
| EP (1) | EP1468009B1 (enExample) |
| JP (1) | JP4378173B2 (enExample) |
| KR (1) | KR100880828B1 (enExample) |
| CN (1) | CN1272341C (enExample) |
| AT (1) | ATE449784T1 (enExample) |
| AU (1) | AU2002347550B2 (enExample) |
| CA (1) | CA2471717C (enExample) |
| DE (1) | DE60234535D1 (enExample) |
| DK (1) | DK1468009T3 (enExample) |
| ES (1) | ES2350880T3 (enExample) |
| IL (2) | IL162789A0 (enExample) |
| NO (1) | NO329024B1 (enExample) |
| NZ (1) | NZ534151A (enExample) |
| RU (1) | RU2303040C2 (enExample) |
| SE (1) | SE0104462D0 (enExample) |
| WO (1) | WO2003055900A1 (enExample) |
| ZA (1) | ZA200405135B (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1359722A1 (en) * | 2002-03-27 | 2003-11-05 | BRITISH TELECOMMUNICATIONS public limited company | Data streaming system and method |
| WO2006077428A1 (en) | 2005-01-21 | 2006-07-27 | Astex Therapeutics Limited | Pharmaceutical compounds |
| JP5528807B2 (ja) | 2006-10-12 | 2014-06-25 | アステックス、セラピューティックス、リミテッド | 複合薬剤 |
| US8916552B2 (en) | 2006-10-12 | 2014-12-23 | Astex Therapeutics Limited | Pharmaceutical combinations |
| EP2062909A1 (en) * | 2007-11-21 | 2009-05-27 | SOLVAY (Société Anonyme) | Peptide production and purification process |
| US9051349B2 (en) | 2007-11-21 | 2015-06-09 | Alba Therapeutics Corporation | Larazotide acetate compositions |
| US20120149868A1 (en) * | 2008-05-15 | 2012-06-14 | Novo Nordisk A/S | Purification of peptides prepared by solid phase synthesis |
| CN102482326A (zh) * | 2009-04-10 | 2012-05-30 | 科登制药科罗拉多公司 | 分离治疗用肽的方法 |
| JP6366111B2 (ja) | 2012-12-13 | 2018-08-01 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | 有効性の改善および毒性の減少のための、抗体およびｓｎ−３８からなるイムノコンジュゲートの投薬 |
| WO2015012904A2 (en) | 2012-12-13 | 2015-01-29 | Immunomedics, Inc. | Antibody-sn-38 immunoconjugates with a cl2a linker |
| US9931417B2 (en) | 2012-12-13 | 2018-04-03 | Immunomedics, Inc. | Antibody-SN-38 immunoconjugates with a CL2A linker |
| EP3024460B1 (en) * | 2013-07-23 | 2020-07-22 | Immunomedics, Inc. | Method for producing antibody-sn-38 immunoconjugates with a cl2a linker |
| CA3016917A1 (en) | 2016-04-27 | 2017-11-02 | Immunomedics, Inc. | Efficacy of anti-trop-2-sn-38 antibody drug conjugates for therapy of tumors relapsed/refractory to checkpoint inhibitors |
| JP2020512314A (ja) | 2017-03-27 | 2020-04-23 | イミューノメディクス、インコーポレイテッドＩｍｍｕｎｏｍｅｄｉｃｓ， Ｉｎｃ． | サシツズマブゴビテカンとＲＡＤ５１阻害剤を用いたＴｒｏｐ−２発現トリプルネガティブ乳癌の治療 |
| CN110352201A (zh) | 2017-04-03 | 2019-10-18 | 免疫医疗公司 | 用于癌症疗法的抗体药物缀合物的皮下施用 |
| CN113952944B (zh) * | 2021-12-23 | 2022-03-29 | 浙江湃肽生物有限公司深圳分公司 | 一种纯化九肽-1的方法 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8317697D0 (en) * | 1983-06-29 | 1983-08-03 | Shell Int Research | Dissolution of peptides in non-aqueous and mixed non-aqueous/aqueous solvents |
| DE4001238A1 (de) * | 1990-01-18 | 1991-07-25 | Basf Ag | Verfahren zur anreicherung bzw. reinigung von biomolekuelen |
| DE19544212A1 (de) * | 1995-11-28 | 1997-06-05 | Asta Medica Ag | Neue LH-RH-Antagonisten mit verbesserter Wirkung |
| DE19813849A1 (de) * | 1998-03-27 | 1999-09-30 | Degussa | Verfahren zur einstufigen Umsalzung und Aufreinigung von Oligopeptiden |
| EP0998940A1 (en) | 1998-09-30 | 2000-05-10 | Laboratoire Theramex | Pharmaceutical compositions based on alpha-cyclodextrin for the oral administration of LH-RH analogues |
| DE19911771B4 (de) * | 1999-03-17 | 2006-03-30 | Zentaris Gmbh | LHRH-Antagonist, Verfahren zu seiner Herstellung und seiner Verwendung |
-
2001
- 2001-12-29 SE SE0104462A patent/SE0104462D0/xx unknown
-
2002
- 2002-12-23 US US10/500,302 patent/US7057014B2/en not_active Expired - Fee Related
- 2002-12-23 DE DE60234535T patent/DE60234535D1/de not_active Expired - Lifetime
- 2002-12-23 EP EP02783479A patent/EP1468009B1/en not_active Expired - Lifetime
- 2002-12-23 NZ NZ534151A patent/NZ534151A/en not_active IP Right Cessation
- 2002-12-23 ES ES02783479T patent/ES2350880T3/es not_active Expired - Lifetime
- 2002-12-23 CN CNB028283481A patent/CN1272341C/zh not_active Expired - Fee Related
- 2002-12-23 DK DK02783479.5T patent/DK1468009T3/da active
- 2002-12-23 RU RU2004119965/04A patent/RU2303040C2/ru not_active IP Right Cessation
- 2002-12-23 JP JP2003556430A patent/JP4378173B2/ja not_active Expired - Fee Related
- 2002-12-23 AT AT02783479T patent/ATE449784T1/de not_active IP Right Cessation
- 2002-12-23 KR KR1020047010363A patent/KR100880828B1/ko not_active Expired - Fee Related
- 2002-12-23 WO PCT/IB2002/005581 patent/WO2003055900A1/en not_active Ceased
- 2002-12-23 CA CA2471717A patent/CA2471717C/en not_active Expired - Fee Related
- 2002-12-23 AU AU2002347550A patent/AU2002347550B2/en not_active Ceased
- 2002-12-23 IL IL16278902A patent/IL162789A0/xx unknown
-
2004
- 2004-06-28 ZA ZA2004/05135A patent/ZA200405135B/en unknown
- 2004-06-29 IL IL162789A patent/IL162789A/en not_active IP Right Cessation
- 2004-07-16 NO NO20043046A patent/NO329024B1/no not_active IP Right Cessation
Also Published As
| Publication number | Publication date |
|---|---|
| SE0104462D0 (sv) | 2001-12-29 |
| EP1468009B1 (en) | 2009-11-25 |
| DK1468009T3 (da) | 2010-04-06 |
| RU2004119965A (ru) | 2006-01-10 |
| CA2471717A1 (en) | 2003-07-10 |
| CN1625561A (zh) | 2005-06-08 |
| DE60234535D1 (de) | 2010-01-07 |
| AU2002347550A1 (en) | 2003-07-15 |
| US20060014694A1 (en) | 2006-01-19 |
| IL162789A (en) | 2010-04-29 |
| JP2005515217A (ja) | 2005-05-26 |
| KR100880828B1 (ko) | 2009-01-30 |
| KR20040090966A (ko) | 2004-10-27 |
| JP4378173B2 (ja) | 2009-12-02 |
| CA2471717C (en) | 2013-06-18 |
| US7057014B2 (en) | 2006-06-06 |
| CN1272341C (zh) | 2006-08-30 |
| WO2003055900A1 (en) | 2003-07-10 |
| NZ534151A (en) | 2007-05-31 |
| ATE449784T1 (de) | 2009-12-15 |
| AU2002347550B2 (en) | 2008-01-03 |
| HK1076112A1 (en) | 2006-01-06 |
| ES2350880T3 (es) | 2011-01-27 |
| IL162789A0 (en) | 2005-11-20 |
| ZA200405135B (en) | 2005-08-31 |
| EP1468009A1 (en) | 2004-10-20 |
| RU2303040C2 (ru) | 2007-07-20 |
| NO20043046L (no) | 2004-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO329024B1 (no) | Peptidrensing | |
| RU2603345C2 (ru) | Циклопептидное соединение высокой чистоты, а также способ его получения и его применение | |
| CN110072878B (zh) | 多粘菌素衍生物及其制备方法和应用 | |
| KR20080091757A (ko) | 에키노칸딘형 화합물의 정제 방법 | |
| JPH05163298A (ja) | 新規ポリペプチドおよびこれを用いる抗ｈｉｖ剤 | |
| JP2012529425A (ja) | デガレリックスの製造方法 | |
| CN102329373A (zh) | 地加瑞克的固相合成工艺 | |
| JP2005515217A5 (enExample) | ||
| CA3050200A1 (en) | Improved process for the preparation of a dodecapeptide | |
| CN100584859C (zh) | 制备棘白菌素衍生物的方法 | |
| ZA200504303B (en) | Process for purifying diacerein | |
| TW201231475A (en) | Method for separating and purifying cyclohexapeptide compound and salt thereof | |
| SU1396970A3 (ru) | Способ получени производных гонадолиберина | |
| CN101781350A (zh) | 一种用混合溶剂纯化熊去氧胆酸的方法 | |
| WO2016012938A2 (en) | Improved process for preparation of amorphous linaclotide | |
| CN113683663A (zh) | 一种机体保护多肽粗品的纯化方法 | |
| CN1763084B (zh) | 高纯度环孢菌素a的制备方法 | |
| NO161374B (no) | Analogifremgangsmaate ved fremstilling av terapeutisk aktive mitomycinanaloger. | |
| HK1076112B (en) | Peptide purification | |
| ES2355280T3 (es) | Procedimientos de purificación de compuestos de tipo equinocandina. | |
| NO771717L (no) | Peptid-derivater og fremgangsm}te for fremstilling av disse | |
| MX2008006361A (en) | Purification processes of echinocandin-type compounds | |
| JPH06256261A (ja) | エンドセリン−１拮抗物質 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |